List of Excipients in Branded Drug SAXENDA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novo Nordisk	SAXENDA	liraglutide	0169-2800	PHENOL	1969-12-31
Novo Nordisk	SAXENDA	liraglutide	0169-2800	PROPYLENE GLYCOL	1969-12-31
Novo Nordisk	SAXENDA	liraglutide	0169-2800	SODIUM PHOSPHATE, DIBASIC, DIHYDRATE	1969-12-31
Novo Nordisk	SAXENDA	liraglutide	0169-2800	WATER	1969-12-31
A-S Medication Solutions	SAXENDA	liraglutide	50090-4257	PHENOL	1969-12-31
A-S Medication Solutions	SAXENDA	liraglutide	50090-4257	PROPYLENE GLYCOL	1969-12-31

Saxenda Excipient Strategy and Commercial Opportunities for Liraglutide Injection

Last updated: October 3, 2026

Saxenda is a once-daily, 6 mg/mL liraglutide injection supplied in a prefilled multidose pen. Its commercial formulation uses a small excipient system: propylene glycol, phenol, disodium phosphate dihydrate, water for injection, and pH adjusters. The strongest opportunities are not broad substitution of excipients. They are targeted improvements in preservative systems, container closure, peptide stability, low-volume delivery, and manufacturing robustness.

Novo Nordisk’s formulation creates a relatively narrow design space. Any alternative must preserve liraglutide’s chemical stability, physical stability, sterility, antimicrobial protection, pen compatibility, dose accuracy, and regulatory comparability.

What excipients are used in Saxenda?

Saxenda contains liraglutide at 6 mg/mL in an aqueous formulation. The U.S. prescribing information identifies the following inactive ingredients per milliliter:

Component	Approximate amount	Primary function
Liraglutide	6 mg	Active pharmaceutical ingredient
Propylene glycol	14 mg	Tonicity and formulation stabilizer
Phenol	1.8 mg	Antimicrobial preservative
Disodium phosphate dihydrate	0.25 mg	Buffering agent
Water for injection	q.s.	Solvent
Hydrochloric acid or sodium hydroxide	As needed	pH adjustment

The formulation pH is approximately 8.15. Saxenda is administered subcutaneously through a multidose prefilled pen, with doses ranging from 0.6 mg to 3 mg once daily. The pen contains 18 mg liraglutide in 3 mL of solution. (Novo Nordisk, 2024a)

Propylene glycol is a notable formulation choice because it contributes to tonicity while avoiding the higher ionic strength that can affect peptide aggregation or container interaction. Phenol supports multidose pen use by limiting microbial growth after repeated needle penetrations.

Why does Saxenda use phenol and propylene glycol?

Phenol is used primarily as a preservative for the multidose presentation. The pen may be used over an extended period after first use, making antimicrobial protection a core product requirement. Phenol is also used in several peptide and protein products, including certain insulin formulations.

Propylene glycol contributes to isotonicity and may support the physical stability of the peptide in solution. It is distinct from polysorbates, which are common in biologic formulations but can introduce peroxide-related degradation, subvisible particles, and container interaction risks.

The excipient system appears designed around four constraints:

1. Maintaining liraglutide in a clear aqueous solution.
2. Preserving the product during repeated use.
3. Supporting accurate delivery through a fine-gauge pen needle.
4. Limiting the number of excipients that can create new degradation pathways.

The absence of a surfactant is commercially relevant. A competitor seeking to replace phenol or propylene glycol cannot assume that a conventional protein formulation containing polysorbate, sucrose, or a larger buffer system will be equivalent.

What formulation patents protect liraglutide injection products?

Liraglutide protection has historically rested more heavily on active-ingredient, peptide-structure, composition-of-matter, manufacturing, and use patents than on the marketed Saxenda excipient combination alone.

Key patent categories include:

Patent category	Relevance to Saxenda
Acylated GLP-1 analogs	Covers liraglutide-type molecular structures and related analogs
Peptide manufacturing	Covers synthesis, purification, acylation, and impurity control
Pharmaceutical compositions	May cover injectable solutions containing liraglutide
Obesity treatment methods	Covers use of liraglutide for weight management
Pen and delivery systems	Covers dose selection, injection devices, and administration methods
Stability and storage	May cover specific conditions or formulation parameters

The commercially important distinction is between a formulation patent and a product-specific excipient claim. A claim directed broadly to "a pharmaceutical composition comprising liraglutide" may be vulnerable if the formulation is disclosed in earlier liraglutide or GLP-1 literature. A narrower claim covering defined concentrations of phenol, propylene glycol, buffer, pH, and storage performance may have greater practical value if it produces an unexpected stability or usability result.

Patent claims directed solely to conventional excipients face a higher obviousness risk. Stronger claims usually connect the excipient range to a measurable technical result, such as reduced aggregation, lower degradation products, improved pen delivery, or preserved antimicrobial effectiveness after repeated use.

When does Saxenda lose exclusivity?

Saxenda’s exclusivity analysis has several layers:

Exclusivity layer	Commercial effect
Active-ingredient patents	Can delay liraglutide entry across multiple products
Formulation patents	Can restrict the specific injectable composition
Method-of-use patents	Can affect obesity and weight-management labeling
Device patents	Can constrain pen-based presentation
Regulatory exclusivity	Can delay certain abbreviated applications
Manufacturing know-how	Can create practical barriers after patent expiry

U.S. market entry depends on the live patent and regulatory record rather than on a single expiration date. FDA Orange Book listings identify patents submitted for approved products, but not every patent relevant to a generic or follow-on strategy. (FDA, 2024a)

For liraglutide, the principal commercial issue is the separation between diabetes use under Victoza and chronic weight management under Saxenda. A generic applicant may seek approval for a narrower indication if a weight-management method patent remains enforceable. The label strategy can therefore affect launch timing even when the underlying molecule is available.

Is Saxenda subject to biosimilar competition?

Saxenda is not a conventional biologic for purposes of the U.S. biosimilar pathway. Liraglutide is a chemically defined peptide drug, and an applicant would generally evaluate the abbreviated new drug application pathway under section 505(j), subject to FDA’s treatment of the reference product and the applicable patent record.

The competitive risk is therefore different from products such as insulin analogs or monoclonal antibodies. A liraglutide competitor must address:

• Peptide identity and sequence;
• Acylation and positional specificity;
• Impurity profile;
• Aggregation and degradation;
• Sterility and particulate control;
• Pen dose accuracy;
• Comparative pharmacokinetics;
• Device and container compatibility.

The principal technical challenge is not simply reproducing the excipient list. It is manufacturing liraglutide with an impurity and stability profile that supports pharmaceutical equivalence and bioequivalence.

What excipient strategies could support a generic Saxenda product?

Preservative replacement

A competitor could evaluate alternatives to phenol, including m-cresol, benzyl alcohol, or combinations of antimicrobial agents. The commercial case would depend on whether the replacement improves tolerability, reduces extractables and leachables concerns, or provides better stability.

The regulatory burden is substantial. A preservative change can affect:

• Antimicrobial effectiveness;
• Local injection-site tolerability;
• Peptide stability;
• Pen component compatibility;
• Multidose in-use stability;
• Extractables and leachables;
• Container closure integrity.

A phenol-free product could have commercial value for patients with preservative sensitivity or for markets that favor lower preservative exposure. It would not automatically receive a substitution advantage.

Propylene glycol optimization

Propylene glycol could be replaced or combined with sodium chloride, glycerol, mannitol, or another tonicity modifier. The critical variables are osmolality, pH, viscosity, peptide solubility, and injection force.

A lower-viscosity formulation could support finer needles or lower injection force. A more concentrated formulation could reduce injection volume, although concentration changes may affect aggregation and local tolerability.

Buffer redesign

The phosphate system is limited in concentration. Alternatives such as histidine, citrate, acetate, or tromethamine could be screened, but each creates a different chemical environment.

Buffer selection can influence:

• Deamidation;
• Oxidation;
• Acyl migration;
• Adsorption to glass or polymer surfaces;
• Metal-ion effects;
• Freeze-thaw behavior;
• pH drift during storage.

A buffer patent is more defensible when the claimed range is linked to a specific stability profile rather than described as one option among many conventional buffers.

Surfactant-free stability

Saxenda’s apparent surfactant-free formulation creates an opportunity for products that maintain stability without polysorbate or poloxamer. This approach may reduce surfactant-related oxidation and particle formation, but it can increase the risk of surface adsorption and interfacial aggregation.

Possible technologies include low-level amino acids, cyclodextrin derivatives, polymeric stabilizers, or optimized container coatings. These strategies require compatibility testing with the pen cartridge, stopper, adhesive, and needle system.

What manufacturing and intellectual-property barriers affect Saxenda competition?

The main barriers are peptide manufacturing and product-device integration.

Peptide manufacturing

Liraglutide is a large, modified peptide. Commercial production requires control over:

• Sequence fidelity;
• Side-chain acylation;
• Truncated and deletion impurities;
• Residual reagents;
• Aggregates;
• Host or process-derived contaminants;
• Purification yield;
• Batch-to-batch consistency.

Process patents may cover selected synthesis or purification steps even when the active-ingredient patent position has weakened. A competing manufacturer may need a non-infringing route with comparable purity and cost.

Cartridge and pen compatibility

The formulation interacts with the primary container and delivery device. Relevant risks include:

• Phenol or propylene glycol interaction with elastomers;
• Silicone oil and particle generation;
• Adsorption to cartridge glass;
• Pen-dose accuracy;
• Needle clogging;
• Extractables and leachables;
• In-use stability after repeated puncture.

A formulation that performs well in vials may fail in a multidose pen. Device patents and design-around requirements can also increase development cost.

What commercial opportunities exist in Saxenda excipient innovation?

Opportunity	Value proposition	Main barrier
Phenol-free multidose formulation	Lower preservative exposure and potential tolerability benefit	Antimicrobial and in-use stability
Lower injection-force formulation	Improved patient usability	Viscosity, osmolality, and device validation
Higher-concentration liraglutide	Smaller injection volume	Peptide aggregation and tolerability
Longer in-use stability	Better adherence and reduced product waste	Microbial control and chemical stability
Robust room-temperature stability	Lower distribution cost	Degradation and container compatibility
Improved cartridge materials	Lower particle and leachable risk	Device redesign and regulatory comparability
Alternative buffer system	Potentially improved stability	New degradation pathways
Preservative and surfactant reduction	Differentiation for sensitive users	Multidose product performance

The highest-value opportunity is likely an integrated formulation-device platform rather than a single excipient substitution. A product that combines lower injection force, improved in-use stability, and a differentiated pen could command commercial attention even without a major change in the active ingredient.

How does Saxenda compare with Wegovy and Zepbound formulations?

Product	Active ingredient	General presentation	Strategic formulation issue
Saxenda	Liraglutide	Daily multidose pen	Preservative, daily use, pen compatibility
Wegovy	Semaglutide	Weekly prefilled pen	High-concentration peptide stability and device delivery
Zepbound	Tirzepatide	Weekly injection	Peptide stability, concentration, and injection usability

Saxenda’s daily dosing creates a larger opportunity for adherence-oriented formulation and device improvements. Weekly competitors reduce dosing frequency, which weakens the commercial impact of incremental excipient advantages.

A Saxenda follow-on product therefore needs either a lower cost structure, superior tolerability, a more convenient device, or a differentiated indication and market-access strategy. Excipient innovation alone is unlikely to overcome a substantial dosing-frequency disadvantage.

What is the FDA regulatory status of Saxenda?

FDA approved Saxenda in December 2014 for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity. FDA later expanded the indication to include pediatric patients aged 12 years and older with obesity and body weight above the applicable threshold. (FDA, 2014; FDA, 2020)

Saxenda is a prescription injectable product. Its regulatory profile requires control of sterility, potency, impurities, particulate matter, container closure integrity, pen functionality, and in-use stability. Any excipient change must be evaluated against pharmaceutical equivalence, bioequivalence, safety, and product-quality requirements.

What is the Orange Book status of Saxenda?

The Orange Book is the principal public source for FDA-listed patents and exclusivity associated with approved drug products. Saxenda’s entry should be reviewed separately from Victoza because the products have different indications, labels, dosage instructions, and regulatory histories, despite sharing liraglutide as the active ingredient. (FDA, 2024a)

For a potential entrant, the relevant review includes:

1. Current Orange Book patent listings for Saxenda.
2. Patent expiration and pediatric-exclusivity dates.
3. Method-of-use claims covering obesity treatment.
4. Any listed formulation or device patents.
5. Paragraph IV certifications and litigation.
6. Carve-out opportunities under a section viii statement.
7. Whether the proposed label would include or omit protected indications.

The public record should be assessed on a product-by-product basis. A challenge to Victoza does not automatically clear all Saxenda-related patent risks.

Which companies are challenging Saxenda?

Public competition in liraglutide has primarily developed around the broader liraglutide market, including diabetes products and potential generic versions. The relevant competitors include generic injectable manufacturers, peptide manufacturers, contract development and manufacturing organizations, and established obesity-drug companies such as Novo Nordisk, Eli Lilly, and companies developing GLP-1 or GLP-1-based therapies.

The commercial threat is likely to emerge in stages:

Stage	Market effect
Patent challenges	Raises litigation and launch-risk questions
Diabetes-market generic entry	Establishes manufacturing and regulatory capability
Weight-management label entry	Directly pressures Saxenda pricing
Pen and formulation differentiation	Creates product-level competition
Weekly GLP-1 competition	Reduces the strategic value of daily liraglutide

A generic launch could initially target diabetes treatment while omitting a protected obesity indication. Later entry into weight management would depend on patent and labeling outcomes.

How strong is the Saxenda excipient patent estate?

The excipient estate is likely weaker than the active-ingredient and manufacturing estate unless claims are tied to narrow composition ranges and demonstrated technical effects. Conventional use of phenol, propylene glycol, phosphate, and water is difficult to protect broadly.

The stronger potential claim types are:

• Defined liraglutide concentration and pH ranges;
• Specific preservative concentrations that extend in-use stability;
• Formulations with reduced aggregation or degradation;
• Compatibility with specified pen or cartridge materials;
• Low-volume or low-force delivery systems;
• Manufacturing processes that reduce peptide impurities;
• Stability profiles linked to defined storage conditions.

A commercially useful patent strategy should combine formulation claims with process, container, device, and method-of-use claims. Reliance on one broad excipient-combination claim creates avoidable design-around risk.

Key Takeaways

• Saxenda uses liraglutide in an aqueous formulation containing propylene glycol, phenol, disodium phosphate dihydrate, and water for injection.
• Phenol supports multidose preservation; propylene glycol contributes to tonicity and formulation performance.
• The most valuable innovation areas are preservative replacement, lower injection force, higher concentration, in-use stability, and cartridge compatibility.
• Liraglutide competition is generally an ANDA and patent-challenge issue rather than a conventional biosimilar issue.
• Saxenda and Victoza require separate Orange Book and method-of-use analyses.
• The strongest intellectual-property strategy combines formulation, manufacturing, device, container, and method-of-use claims.
• Weekly obesity medicines create a significant commercial challenge that excipient improvements alone may not offset.
• Generic launch opportunities are strongest where a manufacturer can combine peptide-cost control with a compliant pen, stable formulation, and a commercially viable label.

FAQs About Saxenda Excipient Strategy

Can phenol be removed from Saxenda?

Yes, a phenol-free formulation is technically possible, but it must demonstrate antimicrobial protection, peptide stability, container compatibility, and acceptable in-use performance for a multidose pen.

Can Saxenda be reformulated as a higher-concentration injection?

Yes, higher concentration is a potential product-development strategy. The main constraints are liraglutide aggregation, viscosity, injection-site tolerability, dose accuracy, and pen-device capability.

Does a new Saxenda excipient combination receive separate patent protection?

It can, but broad claims using conventional excipients face patentability challenges. Protection is stronger when the formulation produces a documented and unexpected technical benefit.

Can a generic liraglutide product omit the obesity indication?

Potentially. A manufacturer may use a section viii statement or a label carve-out if the regulatory and patent record permits omission of a protected method of use.

Is Saxenda commercially attractive after Wegovy and Zepbound?

Saxenda remains relevant as a lower-cost or access-oriented liraglutide product, but daily dosing places it at a commercial disadvantage. A follow-on product would benefit from manufacturing cost reduction, device improvements, or a differentiated formulation.

References

1. U.S. Food and Drug Administration. (2014). FDA approves weight-management drug Saxenda.
2. U.S. Food and Drug Administration. (2020). FDA approves new treatment for chronic weight management, first since 2014.
3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. Novo Nordisk. (2024a). Saxenda prescribing information.
5. Novo Nordisk. (2024b). Annual report 2023.
6. U.S. Food and Drug Administration. (2016). ANDAs for certain highly purified synthetic peptides. Guidance for industry.
7. United States Pharmacopeia. (2024). General chapter <51>: Antimicrobial effectiveness testing.